Compass Pathways (NASDAQ:CMPS) Shares Gap Up – Here’s Why

Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) gapped up prior to trading on Monday . The stock had previously closed at $6.66, but opened at $8.65. Compass Pathways shares last traded at $9.2070, with a volume of 11,603,758 shares trading hands.

Key Compass Pathways News

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: Reports say COMPASS posted Phase 3 wins for its COMP360 program and is advancing toward FDA filing, a direct fundamental driver for future revenue and approval probability. Why COMPASS Pathways (CMPS) Is Up 15.4% After Psilocybin Phase 3 Wins And FDA Filing Momentum
• Positive Sentiment: The White House executive order to accelerate psychedelic research and access has increased the likelihood of faster regulatory review and broader acceptance of psychedelic therapies—an industry-wide catalyst that specifically boosts COMP360’s commercial prospects. Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
• Positive Sentiment: BTIG reaffirmed a “buy” and set a $14 price target, signaling analyst conviction and providing a clear upside anchor for investors. Benzinga
• Positive Sentiment: Unusually large options activity—5,436 call contracts traded (?77% above typical call volume)—suggests speculative and institutional buyers are positioning for further upside. (Intraday trading data)
• Neutral Sentiment: Compass management will appear at the Needham Virtual Psychedelics Forum on April 27, giving the company a platform to update investors on clinical/regulatory strategy—useful for investor relations but not an immediate fundamental change. Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
• Neutral Sentiment: Broad media coverage (CNN, MSN) is amplifying the news flow and likely magnifying intraday volume and volatility, which can accelerate moves but also increase short-term risk. CNN

Analyst Ratings Changes

Several research firms recently commented on CMPS. Royal Bank Of Canada raised their target price on Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. HC Wainwright increased their price target on Compass Pathways from $40.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Morgan Stanley decreased their target price on Compass Pathways from $18.00 to $16.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a research report on Wednesday, January 21st. Finally, Canaccord Genuity Group decreased their target price on Compass Pathways from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, March 26th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Compass Pathways presently has an average rating of “Moderate Buy” and a consensus price target of $21.63.

Compass Pathways Stock Performance

The company has a quick ratio of 0.77, a current ratio of 0.77 and a debt-to-equity ratio of 0.55. The firm has a market cap of $941.83 million, a PE ratio of -3.18 and a beta of 2.01. The firm has a 50-day moving average price of $6.37 and a two-hundred day moving average price of $6.36.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Tuesday, March 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.59). Research analysts forecast that Compass Pathways PLC Sponsored ADR will post -2.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Compass Pathways

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LLC increased its holdings in shares of Compass Pathways by 3.2% in the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock valued at $265,000 after purchasing an additional 1,200 shares during the last quarter. CWM LLC increased its holdings in shares of Compass Pathways by 19.2% in the third quarter. CWM LLC now owns 15,650 shares of the company’s stock valued at $90,000 after purchasing an additional 2,525 shares during the last quarter. Conservest Capital Advisors Inc. increased its holdings in shares of Compass Pathways by 24.6% in the fourth quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock valued at $175,000 after purchasing an additional 5,000 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Compass Pathways in the fourth quarter valued at approximately $38,000. Finally, Raymond James Financial Inc. increased its stake in Compass Pathways by 82.7% during the third quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after acquiring an additional 6,228 shares during the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.